Detalhe da pesquisa
1.
Risk of Gastrointestinal Infections After Initiating Vedolizumab and Anti-TNFα Agents for Ulcerative Colitis.
J Clin Gastroenterol
; 57(7): 714-720, 2023 08 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36156528
2.
P074 Comparative Risk of Clostridioides Difficile Infection in Vedolizumab vs anti-TNFa Agents in Biologic-Naïve Patients With Ulcerative Colitis.
Am J Gastroenterol
; 116(Suppl 1): S19, 2021 Dec 01.
Artigo
Inglês
| MEDLINE | ID: mdl-37461990
3.
Activity of axial spondyloarthritis after one year of anti-tumor necrosis factor therapy among patients with inflammatory bowel diseases.
Clin Rheumatol
; 42(11): 3001-3006, 2023 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-37428414
4.
Outcomes of Standard and Intensified Dosing of Ustekinumab for Chronic Pouch Disorders.
Inflamm Bowel Dis
; 28(1): 146-149, 2022 01 05.
Artigo
Inglês
| MEDLINE | ID: mdl-34245267
5.
Real-World Comparison of Tofacitinib vs Ustekinumab Among Bio-Exposed Patients With Ulcerative Colitis: A Propensity Score Analysis.
Inflamm Bowel Dis
; 27(10): 1694-1697, 2021 10 18.
Artigo
Inglês
| MEDLINE | ID: mdl-33988235